Cargando…

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?

Detalles Bibliográficos
Autores principales:	Franzoi, Maria Alice, de Azambuja, Evandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678394/ https://www.ncbi.nlm.nih.gov/pubmed/33214229 http://dx.doi.org/10.1136/esmoopen-2020-001112

Ejemplares similares

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer
por: Schmid, Peter
Publicado: (2018)

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
por: Emens, Leisha A, et al.
Publicado: (2021)

Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
por: Iwata, Hiroji, et al.
Publicado: (2019)

Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
por: Iwata, Hiroji, et al.
Publicado: (2020)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
por: Emens, L.A., et al.
Publicado: (2020)

Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)
por: Saji, Shigehira, et al.
Publicado: (2022)

Impassable Strictures of the Urethra
por: Roberts, James
Publicado: (1920)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
por: Phua, Lee Cheng, et al.
Publicado: (2020)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
por: Liu, Xiaoyan, et al.
Publicado: (2021)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Impasses na América Latina
Publicado: (2005)

The Treatment of Impassable Urethral Stricture
por: Duke, J.
Publicado: (1896)

The Bristol Royal Infirmary Impasse
por: Williams, P. Watson
Publicado: (1907)

The Bristol Royal Infirmary Impasse
Publicado: (1907)

Misdiagnosis and therapeutic impasse in psychiatry
por: Zrelli, M., et al.
Publicado: (2022)

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
por: Molinero, Luciana, et al.
Publicado: (2019)

An Impasse at the Royal Victoria Infirmary, Newcastle
Publicado: (1908)

Radioimmunotherapy study of (131)I-labeled Atezolizumab in preclinical models of colorectal cancer
por: Zhang, Linhan, et al.
Publicado: (2022)

Role of atezolizumab therapy combined with platinum-based chemotherapy in untreated metastatic urothelial carcinoma – The new landscapes (IMvigor130 trial)
por: Misra, Ankit
Publicado: (2021)

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
por: Røssevold, Andreas Hagen, et al.
Publicado: (2022)

COVID-19:: An impasse between livelihood and health
por: Jayakumar, Karthi
Publicado: (2020)

Cognitive enhancement and authenticity: moving beyond the Impasse
por: Gordon, Emma C.
Publicado: (2022)

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
por: Lux, Michael Patrick, et al.
Publicado: (2021)

El impasse del sujeto : Badiou, la sociología y la modernidad /
por: Olivo Pérez, Miguel Ángel
Publicado: (2017)

Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer
por: Wu, Bin, et al.
Publicado: (2020)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience
por: Franzoi, Maria Alice, et al.
Publicado: (2021)

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
por: Kyte, J. A., et al.
Publicado: (2020)

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
por: Fabi, Alessandra, et al.
Publicado: (2023)

Impassioned observers reveal the world in a grain of sand
por: Doerr, A
Publicado: (2003)

Surveying the Geneva impasse: Coercive care and human rights
por: Martin, Wayne, et al.
Publicado: (2019)

The balloon impasse sign in percutaneous transvenous mitral valvuloplasty
por: Simard, Trevor, et al.
Publicado: (2020)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
por: Sharmni Vishnu, K., et al.
Publicado: (2022)

Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
por: De Giglio, Andrea, et al.
Publicado: (2019)

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
por: Huober, Jens, et al.
Publicado: (2022)

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer
por: Brasó-Maristany, Fara, et al.
Publicado: (2021)

SUN-131 The Roles of Two Insulin Receptor Isoforms in Triple Negative Breast Cancer Growth
por: Kang, Chifei, et al.
Publicado: (2020)

Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature
por: Feng, Dongfeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_duln5eadkppe65vp7ih7vf7rs6